Sugi Predict

Sugi Predict / Compounds / SCHEMBL13664760

SCHEMBL13664760

SCHEMBL13664760

CCOC(=O)C(=CNc1ccc(I)c(Cl)c1)C(=O)OCC

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 5/20 0.62
▸ NPSR1 Q6W5P4 5/20 0.61
▸ MAPT P10636 5/20 0.61
▸ KDM4E B2RXH2 4/20 0.61
▸ RECQL P46063 1/20 0.61
▸ TDP1 Q9NUW8 2/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ HPGD P15428 2/20 0.52
▸ MEN1 O00255 3/20 0.50
▸ KMT2A Q03164 3/20 0.50
▸ GAA P10253 3/20 0.49
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.46
▸ NPY1R P25929 1/20 0.46
▸ NPY2R P49146 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ ERBB2 P04626 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12682622 0.94 NPSR1 (0.55) DHODHNPSR1MAPTKDM4ERECQL
SCHEMBL10862238 0.88 DHODH (0.67) DHODHNPSR1MAPTKDM4ERECQL
SCHEMBL10862565 0.86 DHODH (0.65) DHODHNPSR1MAPTKDM4ERECQL
SCHEMBL11389721 0.84 DHODH (0.62) DHODHNPSR1MAPTKDM4ERECQL
SCHEMBL9082408 0.84 DHODH (0.62) DHODHNPSR1MAPTKDM4ERECQL
SCHEMBL15053652 0.83 DHODH (0.60) DHODHNPSR1MAPTKDM4ERECQL
SCHEMBL31080679 0.82 DHODH (0.62) DHODHNPSR1MAPTKDM4ERECQL
SCHEMBL21050681 0.82 DHODH (0.62) DHODHNPSR1MAPTKDM4ERECQL
SCHEMBL18987933 0.82 DHODH (0.62) DHODHNPSR1MAPTKDM4ERECQL
SCHEMBL10863692 0.81 DHODH (0.90) DHODHNPSR1MAPTKDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20220242875-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2022-08-04 — — US disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
US-20090258853-A1 Somatostatin Agonists MERCK SHARP & DOHME CORP. 2009-10-15 — — US disclosed
US-20090258853-A1 Somatostatin Agonists MERCK SHARP & DOHME CORP. 2009-10-15 — — US disclosed
WO-2008051272-A2 SOMATOSTATIN AGONISTS MERCK & CO., INC. (US) 2008-05-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258853-A1 Somatostatin Agonists SSTR2, SSTR3, SSTR1 DHODH 4521/4885NPSR1 33/4885MAPT 2525/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS DHODH 4336/4885NPSR1 4345/4885MAPT 229/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS DHODH 4096/4885NPSR1 4618/4885MAPT 761/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS DHODH 4096/4885NPSR1 4618/4885MAPT 761/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS DHODH 4430/4885NPSR1 4528/4885MAPT 279/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS DHODH 4430/4885NPSR1 4528/4885MAPT 279/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS DHODH 4430/4885NPSR1 4528/4885MAPT 279/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS DHODH 4430/4885NPSR1 4528/4885MAPT 279/4885
US-20220242875-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS DHODH 4430/4885NPSR1 4528/4885MAPT 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.